Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

NCT06497530 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Extensive-Stage Small Cell Lung Cancer

Interventions

DRUG: Serplulimab
DRUG: Lurbinectedin
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

Guangzhou Institute of Respiratory Disease